Search

Your search keyword '"Shi, Guo-Hai"' showing total 198 results
Start Over Author "Shi, Guo-Hai"
198 results on '"Shi, Guo-Hai"'

9. The Inflammasomes Adaptor Protein PYCARD Is a Potential Pyroptosis Biomarker Related to Immune Response and Prognosis in Clear Cell Renal Cell Carcinoma

Author

Su, Jia-Qi, primary, Tian, Xi, additional, Xu, Wen-Hao, additional, Anwaier, Aihetaimujiang, additional, Ye, Shi-Qi, additional, Zhu, Shu-Xuan, additional, Wang, Yue, additional, Gu, Jun, additional, Shi, Guo-Hai, additional, Qu, Yuan-Yuan, additional, Zhang, Hai-Liang, additional, and Ye, Ding-Wei, additional

Published
2022
Full Text
View/download PDF

14. Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response

Author

Tian, Xi, primary, Xu, Wen-Hao, additional, Xu, Fu-Jiang, additional, Li, Hui, additional, Anwaier, Aihetaimujiang, additional, Wang, Hong-Kai, additional, Wan, Fang-Ning, additional, Zhu, Yu-, additional, Cao, Da-Long, additional, Zhu, Yi-Ping, additional, Shi, Guo-Hai, additional, Qu, Yuan-Yuan, additional, Zhang, Hai-Liang, additional, and Ye, Ding-Wei, additional

Published
2022
Full Text
View/download PDF

18. Construction and Validation of a Robust Genomic Classifier for High-Risk Sporadic Type 2 Papillary Renal Cell Carcinoma: Support More Accurate Utilization of mTOR inhibitors

Author

Tian, Xi, primary, Xu, Wen-Hao, additional, Anwaier, Aihetaimujiang, additional, Wang, Yue, additional, Gan, Hua-Lei, additional, Luo, Wen-Jie, additional, Wang, Hong-Kai, additional, Wan, Fang-Ning, additional, Zhu, Yu, additional, Cao, Da-Long, additional, Shi, Guo-Hai, additional, Qu, Yuan-Yuan, additional, Zhang, Hai-Liang, additional, and Ye, Ding-Wei, additional

Published
2021
Full Text
View/download PDF

19. Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real‐world data

Author

Tian, Xi, primary, Xu, Wen‐Hao, additional, Anwaier, Aihetaimujiang, additional, Wang, Hong‐Kai, additional, Wan, Fang‐Ning, additional, Cao, Da‐Long, additional, Luo, Wen‐Jie, additional, Shi, Guo‐Hai, additional, Qu, Yuan‐Yuan, additional, Zhang, Hai‐Liang, additional, and Ye, Ding‐Wei, additional

Published
2021
Full Text
View/download PDF

20. Hexokinase 3 Dysfunction Promotes Tumorigenesis and Immune Escape by Regulating Monocyte/Macrophage Infiltration of Clear Cell Renal Cell Carcinoma Microenvironment

Author

Xu, Wen-Hao, primary, Liu, WangRui, additional, Xu, Yue, additional, Tian, Xi, additional, Anwaier, Aihetaimujiang, additional, Su, Jia-Qi, additional, Zhu, Wen-Kai, additional, Shi, Guo-Hai, additional, Zhong, Chunlong, additional, Qu, Yuan-Yuan, additional, Zhang, Hai-Liang, additional, and Ye, Ding-Wei, additional

Published
2021
Full Text
View/download PDF

21. Hexokinase 3 dysfunction promotes tumorigenesis and immune escape by upregulating monocyte/macrophage infiltration into the clear cell renal cell carcinoma microenvironment

Author

Xu, Wenhao, primary, Liu, Wang-Rui, additional, Xu, Yue, additional, Tian, Xi, additional, Anwaier, Aihetaimujiang, additional, Su, Jia-Qi, additional, Zhu, Wen-Kai, additional, Shi, Guo-Hai, additional, Wei, Gao-Meng, additional, Huang, Yong-Ping, additional, Qu, Yuan-Yuan, additional, Zhang, Hai-Liang, additional, and Ye, Ding-Wei, additional

Published
2021
Full Text
View/download PDF

22. Identification and validation of novel metastasis-related signatures of clear cell renal cell carcinoma using gene expression databases

Author

Ma, Chun-Guang, Xu, Wen-Hao, Xu, Yue, Wang, Jun, Liu, Wang-Rui, Cao, Da-Long, Wang, Hong-Kai, Shi, Guo-Hai, Zhu, Yi-Ping, Qu, Yuan-Yuan, Zhang, Hai-Liang, and Ye, Ding-Wei

Subjects
Original Article
Abstract

Patients with clear cell renal cell carcinoma (ccRCC) typically face aggressive disease progression when metastasis occurs. Here, we screened and identified differentially expressed genes in three microarray datasets from the Gene Expression Omnibus database. We identified 112 differentially expressed genes with functional enrichment as candidate prognostic biomarkers. Lasso Cox regression suggested 10 significant oncogenic hub genes involved in earlier recurrence and poor prognosis of ccRCC. Receiver operating characteristic curves validated the specificity and sensitivity of the Cox regression penalty used to predict prognosis. The area under the curve indexes of the integrated genes scores were 0.758 and 0.772 for overall and disease-free survival, respectively. The prognostic values of ADAMTS9, C1S, DPYSL3, H2AFX, MINA, PLOD2, RUNX1, SLC19A1, TPX2, and TRIB3 were validated through an analysis of 10 hub genes in 380 patients with ccRCC from a real-world cohort. The expression levels of were of high prognostic value for predicting metastatic potential. These findings will likely significantly contribute to our understanding of the underlying mechanisms of ccRCC, which will enhance efforts to optimize therapy.

Published
2020

25. Large‐scale transcriptome profiles reveal robust 20‐signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma

Author

Xu, Wen‐Hao, primary, Xu, Yue, additional, Tian, Xi, additional, Anwaier, Aihetaimujiang, additional, Liu, Wang‐Rui, additional, Wang, Jun, additional, Zhu, Wen‐Kai, additional, Cao, Da‐Long, additional, Wang, Hong‐Kai, additional, Shi, Guo‐Hai, additional, Qu, Yuan‐Yuan, additional, Zhang, Hai‐Liang, additional, and Ye, Ding‐Wei, additional

Published
2020
Full Text
View/download PDF

27. Fatty acid synthase (FASN), a novel signature for visceral adipose tissues, regulates proliferation, migration and predicts prognosis of clear cell renal cell carcinoma

Author

Xu, Wen-Hao, primary, Anwaier, Aihetaimujiang, additional, Wang, Hong-Kai, additional, Wang, Jun, additional, Zhu, Wen-Kai, additional, Tian, Xi, additional, Ma, Chung-Guang, additional, Wan, Fang-Ning, additional, Cao, Da-Long, additional, Shi, Guo-Hai, additional, Qu, Yuan-Yuan, additional, Zhang, Hai-Liang, additional, and Ye, Ding-Wei, additional

Published
2020
Full Text
View/download PDF

28. Genome-wide profiling identification of prognostic novel signatures in papillary renal cell carcinoma based on large-scale sequencing data

Author

Tian, Xi, primary, Xu, Wen-Hao, additional, anwaier, Aihetaimujiang, additional, Wang, Hong-Kai, additional, Wan, Fang-Ning, additional, Zhu, Yu, additional, Cao, Da-Long, additional, Zhu, Yi-Ping, additional, Shi, Guo-Hai, additional, Qu, Yuan-Yuan, additional, Zhang, Hai-Liang, additional, and Ye, Ding-Wei, additional

Published
2020
Full Text
View/download PDF

29. Inactivation of the AMPK–GATA3–ECHS1 Pathway Induces Fatty Acid Synthesis That Promotes Clear Cell Renal Cell Carcinoma Growth

Author

Qu, Yuan-Yuan, primary, Zhao, Rui, additional, Zhang, Hai-Liang, additional, Zhou, Qian, additional, Xu, Fu-Jiang, additional, Zhang, Xuan, additional, Xu, Wen-Hao, additional, Shao, Ning, additional, Zhou, Shu-Xian, additional, Dai, Bo, additional, Zhu, Yao, additional, Shi, Guo-Hai, additional, Shen, Yi-Jun, additional, Zhu, Yi-Ping, additional, Han, Cheng-Tao, additional, Chang, Kun, additional, Lin, Yan, additional, Zang, Wei-Dong, additional, Xu, Wei, additional, Ye, Ding-Wei, additional, Zhao, Shi-Min, additional, and Zhao, Jian-Yuan, additional

Published
2020
Full Text
View/download PDF

33. The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma

Author

Xiao, Wen-jun, primary, Xu, Fu-jiang, additional, Zhang, Xuan, additional, Zhou, Shu-xian, additional, Zhang, Hai-liang, additional, Dai, Bo, additional, Zhu, Yao, additional, Shi, Guo-hai, additional, Shen, Yi-jun, additional, Zhu, Yi-ping, additional, Qu, Yuan-yuan, additional, Zhao, Jian-yuan, additional, and Ye, Ding-wei, additional

Published
2019
Full Text
View/download PDF

36. Yolk sac tumor in a patient with transverse testicular ectopia

Author

Zhu Yi-Ping, Zhang Shi-Lin, Ye Ding-Wei, Shi Guo-hai, and Xiao Wen-jun

Subjects
Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Transverse testicular ectopia (TTE) is a rare anomaly in which both testes descend through a single inguinal canal. We report a case of yolk sac tumor in the ectopic testis of a patient with TTE. A 24-year-old man presented to our hospital with a left inguinal-mass, right cryptorchidism and elevated alpha-fetoprotein (AFP). A left herniotomy 3 years earlier demonstrated both testes in the left scrotum, one above another positionally. Four months ago, a left scrotal mass appeared and radical orchiectomy of both testes revealed testicular yolk sac tumor of the ectopic testis. An enlarging left inguinal-mass appeared 2 months ago and he was referred to our hospital. Laboratory data showed an elevation of AFP (245.5 ng/ml) and a 46 XY karyotype. He underwent bilateral retroperitoneal lymph node dissection and simultaneous left inguinal mass dissection. Histopathologic examination revealed a diagnosis of recurrent yolk sac tumor in the left inguinal mass. The retroperitoneal lymph node was not enlarged and, on histopathology, was not involved. The patient has now been followed up for 8 months without evidence of biochemical or radiological recurrence.

Published
2011
Full Text
View/download PDF

39. MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai

Author

Wu, Jun-Long, primary, Zhou, Shu-Xian, additional, Zhao, Rui, additional, Zhang, Xuan, additional, Chang, Kun, additional, Gu, Cheng-Yuan, additional, Gan, Hua-Lei, additional, Dai, Bo, additional, Zhu, Yao, additional, Zhang, Hai-Liang, additional, Shi, Guo-Hai, additional, Qu, Yuan-Yuan, additional, Zhao, Jian-Yuan, additional, and Ye, Ding-Wei, additional

Published
2016
Full Text
View/download PDF

40. Functional variants of the 5-methyltetrahydrofolate-homocysteine methyltransferase gene significantly increase susceptibility to prostate cancer: Results from an ethnic Han Chinese population

Author

Qu, Yuan-Yuan, primary, Zhou, Shu-Xian, additional, Zhang, Xuan, additional, Zhao, Rui, additional, Gu, Cheng-Yuan, additional, Chang, Kun, additional, Yang, Xiao-Qun, additional, Gan, Hua-Lei, additional, Dai, Bo, additional, Zhang, Hai-Liang, additional, Shi, Guo-Hai, additional, Zhu, Yao, additional, Ye, Ding-Wei, additional, and Zhao, Jian-Yuan, additional

Published
2016
Full Text
View/download PDF

41. Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma.

Author

Wang, Hong‐Kai, Xu, Wen‐Hao, Ma, Chun‐Guang, Shi, Guo‐Hai, Zhang, Hai‐Liang, Ye, Ding‐Wei, and Zhou, Liang‐Ping

Abstract

Objectives: To investigate the role of tumor growth velocity in defining tumor progression in metastatic renal cell carcinoma patients treated with the vascular endothelial growth factor tyrosine kinase inhibitor, sorafenib. Methods: A modified calculation for tumor growth velocity was introduced to evaluate the tumor growth velocity, before and after sorafenib withdrawal. Known prognostic factors together with tumor growth velocity before drug withdrawal and tumor growth velocity after drug withdrawal were compared using a χ2‐test from a contingency table, and partial likelihood test from a Cox regression model for overall survival. Results: A total of 114 patients who reached progressive disease and withdrew from sorafenib were enrolled after a median follow‐up period of 107.8 months. Tumor growth velocity before drug withdrawal was 7.347 ± 4.040, and tumor growth velocity after drug withdrawal was 11.647 ± 5.937 (P < 0.001). Higher tumor growth velocity before drug withdrawal was correlated with a higher risk Memorial Sloan Kettering Cancer Center score (P = 0.022), Karnofsky Performance Status <80 (P = 0.028), non‐clear cell carcinoma (P = 0.037), higher tumor nucleus grade (P < 0.001) and best treatment response (P < 0.001). Patients with tumor growth velocity before drug withdrawal >5.0 had shorter overall survival (P < 0.001). On multivariate analysis, factors associated with overall survival were high/intermediate Memorial Sloan Kettering Cancer Center risk score (hazard ratio 2.119, P = 0.006), non‐clear histological subtype (hazard ratio 1.900, P = 0.031), tumor growth velocity before drug withdrawal ≥5.0 (hazard ratio 2.758, P < 0.001) and progressive disease as best response (hazard ratio 2.069, P = 0.001). Conclusions: Significantly faster tumor growth can be observed if sorafenib is discontinued in the case of disease progression. Thus, we suggest not to withdraw targeted agents until tumor growth velocity is >5.0. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

47. Association of glutathione S-transferase T1 and M1 polymorphisms with prostate cancer susceptibility in populations of Asian descent: a meta-analysis

Author

Cao, Da-Long, primary, Ye, Ding-Wei, additional, Dai, Bo, additional, Zhang, Hai-Liang, additional, Shen, Yi-Jun, additional, Zhu, Yao, additional, Zhu, Yi-Ping, additional, Shi, Guo-Hai, additional, Ma, Chun-Guang, additional, Xiao, Wen-Jun, additional, Qin, Xiao-Jian, additional, and Lin, Guo-Wen, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results